

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antithrombotics (2014) - Novartis : Hypertension (2014-2015) - Boehringer-Ingelheim : Oral anticoagulation (2014-2015) - Sanofi Aventis : Hyperlipidemia (2014-2015-2016) - Bayer Healthcare : Oral anticoagulation (2014-2015-2016) - Pfizer/BMS alliance : Oral anticoagulation (2014-2015-2016) - MSD : Antiplatelet therapy (2016) - Astrazeneca : Antiplatelet therapy (2016) - AbbiVie : cachexia (2016) - Novartis : Heart Failure (2016)
Asteggiano Riccardo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Rosuvastatin (2014) - Edwards Lifesciences : Prosthetic valves (2015-2016)
Galderisi Maurizio	Nothing to be declared (2014-2015-2016)
Habib Gilbert	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : pulmonary hypertension (2014-2015-2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : pulmonary hypertension (2014)
Lancellotti Patrizio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : nebivolol (2014) - Servier : Imaging Ischemic disease (2015) - Boston Scientific : Sudden death (2015) - St Jude Medical : Echo course (2015-2016) - Servier : Ischemic Heart Disease (2016)

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Bayer : NOAC (2015-2016)</li> </ul>
Lenihan Daniel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Incyte, Inc : Consultant (2014)</li> <li>- Ariad, Inc : Consultant (2014-2015)</li> <li>- Amgen Inc : Cancer therapeutics (2014-2015-2016)</li> <li>- Roche Pharma : DSMB for cancer therapeutic clinical trial (2014-2015-2016)</li> <li>- Bristol Myers Squibb : Cardiac safety of cancer therapeutics (2015-2016)</li> <li>- Acorda, Inc : Heart Failure therapeutics (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Takeda Pharmaceuticals : Cardiac Safety in Relapsed Myeloma (2014-2015-2016)</li> <li>- Acorda, Inc : Heart Failure (2014-2015-2016)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2014-2015)</li> <li>- Biotronik : atrial fibrillation (2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Medtronic : AF screening (2016)</li> <li>- BMS/Pfizer : Anticoagulation (2016)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	<ul style="list-style-type: none"> <li>- Daiichi-Sankyo : Anticoagulation (2016)</li> <li>- Boehringer Ingelheim : Anticoagulation (2016)</li> <li>- Bayer/Janssen : Anticoagulation (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Boehringer Ingelheim : AF Registries [unrestricted educational grant] (2016)</li> <li>- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)</li> </ul>
Lopez Fernandez Teresa	Nothing to be declared (2014-2015-2016)
Lyon Alexander	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Clovis Oncology : Cardiotoxicity of cancer drugs (2014)</li> <li>- Roche Pharma : Heart failure (2014)</li> <li>- Eporgen : Heart failure (2014)</li> <li>- Celladon : Gene therapy (2014-2015)</li> <li>- Bayer : Anticoagulation (2014-2015-2016)</li> <li>- Pfizer : Cardiotoxicity of cancer drugs (2014-2015-2016)</li> <li>- Amgen Inc : Cardiotoxicity of cancer drugs (2014-2015-2016)</li> <li>- Ferring International : Cardiotoxicity of cancer drugs (2014-2015-2016)</li> <li>- Clinigen Group : Cardioxane (2014-2015-2016)</li> <li>- Servier : Ivabradine, S44121 (2014-2015-2016)</li> <li>- Novartis : Heart failure (2015-2016)</li> <li>- Eli Lilly : Oncology drugs (2015-2016)</li> <li>- Stealth Peptides : Heart failure (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Celladon : Gene therapy (2014-2015)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lyon Alexander	<ul style="list-style-type: none"> <li>- Pfizer : Cardiotoxicity of cancer drugs (2014-2015-2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Servier : Heart failure (2014-2015)</li> <li>- Pfizer : Cardiotoxicity (2014-2015-2016)</li> </ul> </li> </ul>
Mohty Dania	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Speaker fees (2014)</li> <li>- Boehringer-Ingelheim : Speaker fees, product Pradaxa (2014)</li> <li>- Servier : Speaker fees (2014-2015)</li> <li>- Toshiba medical imaging : Speaker fees, product Artida (2014-2015)</li> <li>- Novartis : Speaker fees (2014-2015-2016)</li> <li>- Teva Pharmaceutical Industries : speaker fees (2016)</li> <li>- AbbiVie : speaker fees (2016)</li> <li>- Prothena : speaker fees (2016)</li> </ul>
Piepoli Massimo Francesco	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015-2016)</li> <li>- Novartis : Heart Failure Prevention Initiatives (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure Prevention Initiatives (2015-2016)</li> </ul>
Rodriguez Munoz Daniel	Nothing to be declared (2014-2015-2016)
Suter Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Teva Pharmaceutical Industries : Cancer Therapeutics (2014)</li> <li>- Novartis : Heart Failure (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis, Amgen : Heart Failure, Cancer (2015)</li> <li>- Johnson &amp; Johnson : Cancer (2016)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Suter Thomas	<ul style="list-style-type: none"> <li>- Roche Pharma : Cancer (2016)</li> <li>- Novartis : Heart Failure (2016)</li> </ul>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Ranolazine (2014)</li> <li>- Menarini : Angina, diabetes (2015-2016)</li> <li>- Servier : Antiarrhythmic, angina (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca (Unrestricted Grant) : Candesartan, Felodipine, Atenolol (2014)</li> <li>- Servier : Committee Member (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : No product/device (2014)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015-2016)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2014-2015-2016)</li> <li>- Teva Pharmaceutical Industries : anti-cancer treatment (2015-2016)</li> <li>- Sanofi Aventis : anticoagulants (2015-2016)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015-2016)</li> <li>- United Therapeutics : pulmonary hypertension (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2014-2015-2016)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> <li>- Philips : 3D Echocardiography. (2016)</li> <li>- Servier : Clinical case presentation during ESC Cong 2016 (2016)</li> <li>- Pfizer : speaker CV risk factors. (2016)</li> <li>- MSD : speaker. CV risk factors (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> <li>- Edwards Lifesciences : Echo for TAVi assessment &amp; Epidemiology of Ao stenosis (2016)</li> <li>- Abbott : Epidemiology study of Mitral regurgitation (2016)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Achenbach Stephan	Nothing to be declared (2015-2016)
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Thermo Fischer Scientific : Cardiac markers (2015) - Vifor International : Heart failure (2015) - Astra Zeneca : Platelet inhibition (2015) - Astra Zeneca : Antiplatelet treatment (2016)
Badimon Lina	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Lipids (2015-2016) - Burson Masteller : Nutrition (2015-2016) - Astra Zeneca : Thrombosis (2015-2016)  D - Research funding (departmental or institutional). - Astrazeneca : Thrombosis (2015-2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Aspirin (2015) - Sanofi Aventis : Clopidogrel (2015) - Daiichi Sankyo : Prasugrel (2015) - Eli Lilly : Prasugrel (2015) - Novartis : Serelaxin, LCZ696 (2015) - Pfizer : Apixaban (2015-2016) - Bristol Myers Squibb : Apixaban (2015-2016) - Servier : ivabradine (2015-2016) - Astra Zeneca : Ticagrelor (2015-2016) - Ferrer Internacional : Trinomia (polypill) (2015-2016) - Janssen-Cilag : GEMINI Trial - RIVAROXACS2002 (2016)

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Novartis : Serelaxin, LCZ696, ACZ885, AHF Academy (2016)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2015-2016)</li> </ul> </li> <li>E - Research funding (personal).               <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2015-2016)</li> </ul> </li> </ul>
Cardinale Daniela	Nothing to be declared (2015-2016)
Carerj Scipione	Nothing to be declared (2015-2016)
Curigliano Giuseppe	Nothing to be declared (2015)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Novartis : Oncology (2016)</li> <li>- Roche Pharma : Oncology (2016)</li> </ul>
de Azambuja Evandro	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- GlaxoSmithKline : Lapatinib (2015-2016)</li> <li>- Roche Pharma : trastuzumab (2015-2016)</li> </ul> B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Roche Pharma : Trastuzumab, TDM1, Pertuzumab (2015-2016)</li> </ul>
Dent Susan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Hoffman La Roche : Advisory board (2015-2016)</li> <li>- Novartis : Advisory board (2015-2016)</li> <li>- Amgen : Honoraria (2015-2016)</li> </ul> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Hoffman La Roche : Taselisib - P13k inhibitor in women with metastatic breast cancer (2015-2016)</li> </ul>
Erol Cetin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Servier : Hypertension (2015-2016)</li> </ul> B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Menarini : Hypertension (2015-2016)</li> </ul>
Ewer Michael	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Bayer : Cardiotoxicity of anti-cancer agents (2015)</li> </ul>



## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ewer Michael	<ul style="list-style-type: none"> <li>- Astra Zeneca : Cardiotoxicity of anti-cancer agents (2015-2016)</li> <li>- Roche Pharma : Cardiotoxicity of anti-cancer agents (2015-2016)</li> <li>- Galena : Cardiotoxicity of anti-cancer agents (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Book royalties : People's publishing (2015-2016)</li> </ul>
Farmakis Dimitrios T	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure (2015)</li> <li>- Servier : Heart Failure (2015-2016)</li> </ul>
Fietkau Rainer	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sennewald GmbH : radiotherapy (2015)</li> <li>- Fresenius Nutrition : nutrition (2015-2016)</li> <li>- Lilly : radiotherapy; medical oncology (2015-2016)</li> <li>- Roche Pharma : radiotherapy; medical oncology (2015-2016)</li> <li>- Brainlab : radiotherapy; medical oncology (2015-2016)</li> <li>- Merck Oncology : radiotherapy; medical oncology (2015-2016)</li> <li>- Sennewald GmbH : hytherthermia (2016)</li> <li>- Novocure GmbH : medical device (2016)</li> <li>- MSD : medical oncology (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sennewald GmbH : radiotherapy (2015)</li> <li>- Fresenius Nutrition : Nutrition (2015-2016)</li> <li>- Roche Pharma : radiotherapy; medical oncology (2015-2016)</li> <li>- Brainlab : radiotherapy; medical oncology (2015-2016)</li> <li>- Merck Oncology : radiotherapy; medical oncology (2015-2016)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Fietkau Rainer	<ul style="list-style-type: none"> <li>- Lilly : radiotherapy; medical oncology; (2015-2016)</li> <li>- Sennewald GmbH : hyperthermia (2016)</li> <li>- MSD : medical oncology (2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Lilly : radiotherapy; medical oncology; (2015)</li> <li>- Fresenius Nutrition : Nutrition (2015-2016)</li> <li>- Roche Pharma : radiotherapy; medical oncology (2015-2016)</li> <li>- Brainlab : radiotherapy; medical oncology (2015-2016)</li> <li>- Sennewald GmbH : radiotherapy; medical oncology (2015-2016)</li> <li>- Merck Oncology : radiotherapy; medical oncology (2015-2016)</li> <li>- MSD : medical oncology (2016)</li> <li>- Lilly : radiotherapy; medical oncology (2016)</li> </ul> </li> </ul>
Fitzsimons Donna	<p>Nothing to be declared (2016)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : lipid management (2015)</li> </ul>
Gaemperli Oliver	<p>Nothing to be declared (2016)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : MitraClip (2015)</li> <li>- Biosensors : Travel Grant to AsiaPCR 2015 (2015)</li> </ul>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiovascular (2015)</li> <li>- Medtronic : cardiovascular (2015)</li> <li>- Servier : cardiovascular (2015)</li> <li>- St Jude Medical : cardiovascular (2015)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Sanofi Aventis : cardiovascular (2015)</li> <li>- Meda pharma : cardiovascular (2015)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2015)</li> <li>- Medscape : cardiovascular (2015)</li> <li>- Bayer Vital : cardiovascular (2015)</li> <li>- Correvio : cardiovascular (2015)</li> <li>- Bristol Myers Squibb Global : cardiovascular (2015)</li> <li>- Pfizer Germany : cardiovascular (2015)</li> <li>- Boehringer-Ingelheim : cardiovascular (2015-2016)</li> <li>- Bayer Healthcare : cardiovascular (2015-2016)</li> <li>- Daiichi Sankyo Europe : cardiovascular (2015-2016)</li> <li>- Pfizer Global : cardiovascular (2015-2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Meda pharma : cardiovascular (2015)</li> <li>- Daiichi Sankyo : cardiovascular (2015-2016)</li> <li>- St Jude Medical : cardiovascular (2015-2016)</li> <li>- Sanofi Aventis : cardiovascular (2015-2016)</li> <li>- British Heart Foundation : cardiovascular (2015-2016)</li> <li>- BMS / Pfizer alliance : cardiovascular (2015-2016)</li> <li>- Leducq Foundation : cardiovascular (2015-2016)</li> <li>- European Union FP7 : cardiovascular (2015-2016)</li> <li>- European Union horizon2020 : cardiovascular (2015-2016)</li> </ul> </li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2015-2016)</li> <li>- UK Medical Research Council : cardiovascular (2015-2016)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2015-2016)</li> <li>- B.Braun : Surgical instruments (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : Cardiac valves (2015)</li> <li>- Edwards Lifesciences : Cardiac valves (2015-2016)</li> </ul>
McGale Paul	Nothing to be declared (2015-2016)
Minotti Giorgio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Teva Pharmaceutical Industries : Arsenic trioxide (2015)</li> <li>- Servier : Pixantrone (2015)</li> <li>- Cell Therapeutics BioPharma : Pixantrone (2015)</li> <li>- Ariad : ponatinib (2015)</li> <li>- ARIAD Pharmaceuticals : Hematology (2016)</li> <li>- Servier Italia : Hematology (2016)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Wiley Blackwell : Book (2016)</li> </ul>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : devices (2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Bayer Healthcare : heart failure (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- CIBIEM : heart failure (2015)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- Pfizer : lipids (2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015-2016)</li> <li>- Respicardia : devices (2015-2016)</li> <li>- Novartis : heart failure (2015-2016)</li> <li>- Cardiorentis : heart failure (2015-2016)</li> <li>- Vifor Pharma ltd : heart failure (2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2015-2016)</li> <li>- Amgen : heart failure, lipids (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Celladon : heart failure (2015)</li> <li>- Amgen : heart failure, lipids (2015)</li> <li>- Respicardia : anticoagulant (2015-2016)</li> <li>- BioControl : devices (2015-2016)</li> <li>- DC Device : devices (2015-2016)</li> <li>- Novartis : heart failure (2015-2016)</li> <li>- Cardiorentis : heart failure (2015-2016)</li> <li>- Bayer Healthcare : heart failure (2015-2016)</li> <li>- CIBIEM : heart failure (2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2015-2016)</li> </ul>
Ringwald Juergen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Oral anticoagulant (2015)</li> <li>- Biotest : Oral anticoagulant (2015)</li> <li>- Instrumentation Laboratory : Oral anticoagulants and travel (2015)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ringwald Juergen	<ul style="list-style-type: none"> <li>- Novo-Nordisk : NovoEight (2015-2016)</li> <li>- Boehringer-Ingelheim : Oral anticoagulant (2015-2016)</li> <li>- Daiichi Sankyo : Oral anticoagulant (2015-2016)</li> <li>- Pfizer/BMS : Oral anticoagulant (2015-2016)</li> </ul>
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : coronary catheters (2015-2016)</li> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015-2016)</li> <li>- Terumo Inc : coronary catheters (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2015-2016)</li> <li>- Boston Scientific : devices (2015-2016)</li> <li>- Medtronic : devices (2015-2016)</li> <li>- Biotronik : devices (2015-2016)</li> <li>- Terumo Inc : devices (2015-2016)</li> <li>- Abbott Vascular : devices (2015-2016)</li> </ul>
Schulz-Menger Jeanette	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : CMR Contrast-media (2015)</li> <li>- Berlin Chemie AG : cardiology (2015-2016)</li> <li>- Circle institute : CMR (2016)</li> <li>- Bayer Healthcare : Contrast Media (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : CMR-contrastmedia (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CMR (2015-2016)</li> <li>- Bayer Healthcare : CMR (2016)</li> </ul>

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Schulz-Menger Jeanette	- Circle Cardiovascular Imaging, Inc : CMR (2016)
Stebbing Justin	Nothing to be declared (2015-2016)
Steiner Rudolf	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Clinigen UK : prevention of anthracycline cardiotoxicity / dexrazoxane (2015-2016)
Szmit Sebastian	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer AG : Antithrombotic therapy (2015) - Gilead : Hematology (2015) - Bristol Myers Squibb : Hematology (2015) - Servier : Hematology, Oncology (2015) - Lilly : Oncology (2015) - Teva Pharmaceutical Industries : Oncology, Hematology (2015) - Bayer AG : Antithrombotic treatment (2016) - Teva Pharmaceutical Industries : Hematology, Oncology (2016) - Roche Pharma : Oncology (2016) - Polpharma : Preventive cardiology (2016)
Vaz Carneiro Antonio	Nothing to be declared (2015-2016)
Windecker Stephan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet therapy (2015) - Daiichi Sankyo : Antiplatelet therapy (2015) - Boston Scientific : Complex PCI (2015) - Sanofi Aventis : Managing Dyslipidemia (2015)  D - Research funding (departmental or institutional). - Sorin Group : Electrophysiology (2015) - Biotronik : Electrophysiology (2015)

## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Medicines Company : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Medtronic : Structural Heart Disease (2015)</li> <li>- Novartis : IMP (2015-2016)</li> <li>- Actelion : IMP (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015-2016)</li> <li>- Abbott : PCI and Structural Heart Disease (2015-2016)</li> <li>- Boston Scientific : Structural Heart Disease (2015-2016)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015-2016)</li> <li>- Symetis SA : Structural Heart Disease (2015-2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> <li>- Biotronik : Elektrophysiology (2016)</li> <li>- Amgen : General Cardiology (2016)</li> <li>- Takeda Pharmaceuticals : General Cardiology (2016)</li> <li>- Bristol Myers Squibb : General Cardiology (2016)</li> <li>- Bayer AG : General Cardiology (2016)</li> <li>- Biotest : General Cardiology (2016)</li> <li>- Comed : General Cardiology (2016)</li> <li>- Baxalta : General Cardiology (2016)</li> <li>- Medicure : General Cardiology (2016)</li> </ul>



## 2016 Position Paper Anti-Cancer Treatments and Cardiotoxicity (TF38) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Heart Failure, General Cardiology (2016)</li> <li>- Qvanteq : Invasive Cardiology, PCI (2016)</li> <li>- St. Jude Medical : PCI (2016)</li> <li>- Medtronic : Structural Heart Disease (2016)</li> <li>- NVT AG : Structural Heart Disease (2016)</li> <li>- Quintiles : Structural Heart Disease &amp; PCI (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotics (2014)</li> <li>- Novartis : Hypertension (2014-2015)</li> <li>- Boehringer-Ingelheim : Oral anticoagulation (2014-2015)</li> <li>- Sanofi Aventis : Hyperlipidemia (2014-2015-2016)</li> <li>- Bayer Healthcare : Oral anticoagulation (2014-2015-2016)</li> <li>- Pfizer/BMS alliance : Oral anticoagulation (2014-2015-2016)</li> <li>- MSD : Antiplatelet therapy (2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> <li>- AbbiVie : cachexia (2016)</li> <li>- Novartis : Heart Failure (2016)</li> </ul>
Achenbach Stephan	<p>Nothing to be declared (2015-2016)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2014)</li> </ul>
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</li> <li>- Astra Zeneca : Platelet inhibition (2014-2015)</li> <li>- Vifor International : Heart failure (2015)</li> <li>- Astra Zeneca : Antiplatelet treatment (2016)</li> </ul>
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD-España : Lipids (2014)</li> <li>- Sanofi Aventis : lipids (2014-2015-2016)</li> <li>- Burson Masteller : nutrition (2014-2015-2016)</li> <li>- Astra Zeneca : thrombosis (2014-2015-2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Badimon Lina	D - Research funding (departmental or institutional). - Astrazeneca : thrombosis (2014-2015-2016)
Baron Esquivias Gonzalo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2014-2015-2016) - Daiichi Sankyo : Anticoagulation (2014-2015-2016) - Pfizer : Anticoagulation (2014-2015-2016) - Bayer : Anticoagulation (2014-2016) - Merck Sharp & Dohme : Dyslipemia (2015-2016)
Baumgartner Helmut	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Direct Flow Medical : transcatheter valve implantation (2014-2015) - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2014-2015-2016) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015-2016) - Abbott : transcather mitral valve repair (Mitraclip) (2014-2015-2016) - Edwards Lifesciences : transcatheter valve implantation (2014-2015-2016) - Gore : Occluders for shunt closure (2015-2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Direct Flow Medical : transcatheter valve implantation (2014-2015) - Actelion : Bosentan for PAH treatment in congenital heart disease (2014-2015-2016) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015-2016) - Abbott : transcather mitral valve repair (Mitraclip) (2014-2015-2016) - Edwards Lifesciences : transcatheter valve implantation (2014-2015-2016) - Gore : Occluders for shunt closure (2015-2016)
Bax Jeroen	Nothing to be declared (2014-2015-2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Aspirin, rivaroxaban (2014)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Menarini : Ranolazine (2014)</li> <li>- Novartis : Serelaxin (2014)</li> <li>- Sanofi Aventis : Clopidogrel (2014-2015)</li> <li>- Daiichi Sankyo : Prasugrel (2014-2015)</li> <li>- Eli Lilly : Prasugrel (2014-2015)</li> <li>- Pfizer : Apixaban (2014-2015-2016)</li> <li>- Bristol Myers Squibb : Apixaban (2014-2015-2016)</li> <li>- Servier : ivabradine (2014-2015-2016)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015-2016)</li> <li>- Bayer Healthcare : Aspirin (2015)</li> <li>- Novartis : Serelaxin, LCZ696 (2015)</li> <li>- Ferrer Internacional : Trinomia (polypill) (2015-2016)</li> <li>- Janssen-Cilag : GEMINI Trial - RIVAROXACS2002 (2016)</li> <li>- Novartis : Serelaxin, LCZ696, ACZ885, AHF Academy (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2015-2016)</p> <p>E - Research funding (personal). - Astra Zeneca : Ticagrelor (2014-2015-2016)</p>
Carerj Scipione	Nothing to be declared (2014-2015-2016)
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2014-2015-2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Hypertension (2014-2015-2016)</p>
Fitzsimons Donna	Nothing to be declared (2016)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Fitzsimons Donna	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014) - Amgen : lipid management (2015)
Gaemperli Oliver	Nothing to be declared (2016)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular (2014) - Pfizer : cardiovascular (2014) - Bristol Myers Squibb : cardiovascular (2014) - Medtronic : cardiovascular (2014-2015) - St Jude Medical : cardiovascular (2014-2015) - Sanofi Aventis : cardiovascular (2014-2015) - Meda pharma : cardiovascular (2014-2015) - Merck Sharp & Dohme : cardiovascular (2014-2015) - Medscape : cardiovascular (2014-2015) - Boehringer-Ingelheim : cardiovascular (2014-2015-2016) - Astra Zeneca : cardiovascular (2015) - Servier : cardiovascular (2015) - Bayer Vital : cardiovascular (2015) - Correvio : cardiovascular (2015) - Bristol Myers Squibb Global : cardiovascular (2015)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Pfizer Germany : cardiovascular (2015)</li> <li>- Bayer Healthcare : cardiovascular (2015-2016)</li> <li>- Daiichi Sankyo Europe : cardiovascular (2015-2016)</li> <li>- Pfizer Global : cardiovascular (2015-2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- Daiichi Sankyo : cardiovascular (2014-2015-2016)</li> <li>- St Jude Medical : cardiovascular (2014-2015-2016)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015-2016)</li> <li>- British Heart Foundation : cardiovascular (2014-2015-2016)</li> <li>- BMS / Pfizer alliance : cardiovascular (2014-2015-2016)</li> <li>- Leducq Foundation : cardiovascular (2014-2015-2016)</li> <li>- European Union FP7 : cardiovascular (2014-2015-2016)</li> <li>- European Union horizon2020 : cardiovascular (2014-2015-2016)</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015-2016)</li> <li>- UK Medical Research Council : cardiovascular (2015-2016)</li> </ul> </li> </ul>
Kolh Philippe H	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2014-2015-2016)</li> <li>- B.Braun : Surgical instruments (2014-2015-2016)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medtronic : Cardiac valves (2014-2015)</li> <li>- Edwards Lifesciences : Cardiac valves (2014-2015-2016)</li> </ul> </li> </ul>
Lancellotti Patrizio	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Menarini : nebivolol (2014)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> <li>- Servier : Imaging Ischemic disease (2015)</li> <li>- Boston Scientific : Sudden death (2015)</li> <li>- St Jude Medical : Echo course (2015-2016)</li> <li>- Servier : Ischemic Heart Disease (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Bayer : NOAC (2015-2016)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2014-2015)</li> <li>- Biotronik : atrial fibrillation (2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Medtronic : AF screening (2016)</li> <li>- BMS/Pfizer : Anticoagulation (2016)</li> <li>- Daiichi-Sankyo : Anticoagulation (2016)</li> <li>- Boehringer Ingelheim : Anticoagulation (2016)</li> <li>- Bayer/Janssen : Anticoagulation (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Boehringer Ingelheim : AF Registries [unrestricted educational grant] (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)
Nihoyannopoulos Petros	Nothing to be declared (2014-2015-2016)
Piepoli Massimo Francesco	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015-2016)</li> <li>- Novartis : Heart Failure Prevention Initiatives (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure Prevention Initiatives (2015-2016)</li> </ul>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Boehringer-Ingelheim : anticoagulant (2014)</li> <li>- Respicardia : anticoagulant (2014)</li> <li>- Johnson &amp; Johnson : heart failure (2014)</li> <li>- Pfizer : heart failure, anticoagulant (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Novartis : heart failure (2014-2015-2016)</li> <li>- Cardiorentis : heart failure (2014-2015-2016)</li> <li>- Vifor Pharma Ltd : heart failure (2014-2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015-2016)</li> <li>- Amgen : heart failure, lipids (2014-2015-2016)</li> <li>- BioControl : devices (2015)</li> </ul>



## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- Pfizer : lipids (2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015-2016)</li> <li>- Respicardia : devices (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Vifor Pharma ltd : heart failure (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- Respicardia : anticoagulant (2014-2015-2016)</li> <li>- Novartis : heart failure (2014-2015-2016)</li> <li>- Cardiorientis : heart failure (2014-2015-2016)</li> <li>- Bayer Healthcare : heart failure (2014-2015-2016)</li> <li>- CIBIEM : heart failure (2014-2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015-2016)</li> <li>- Celladon : heart failure (2015)</li> <li>- BioControl : devices (2015-2016)</li> <li>- DC Device : devices (2015-2016)</li> </ul>
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : coronary catheters (2014-2015-2016)</li> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015-2016)</li> <li>- Terumo Inc : coronary catheters (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2014-2015-2016)</li> <li>- Boston Scientific : devices (2014-2015-2016)</li> <li>- Medtronic : devices (2014-2015-2016)</li> <li>- Biotronik : devices (2014-2015-2016)</li> <li>- Abbott Vascular : devices (2014-2015-2016)</li> <li>- Terumo Inc : devices (2015-2016)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015-2016)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2014-2015-2016)</li> <li>- Teva Pharmaceutical Industries : anti-cancer treatment (2015-2016)</li> <li>- Sanofi Aventis : anticoagulants (2015-2016)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015-2016)</li> <li>- United Therapeutics : pulmonary hypertension (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2014-2015-2016)</li> </ul>
Vaz Carneiro Antonio	<p>Nothing to be declared (2015-2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- AbbVie : Oncology (2014)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Antiplatelet therapy (2014)</li> <li>- Bayer Healthcare : Antithrombotic drug (2014)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Abbott : Stent and Heartvalvetherapy (2014)</li> <li>- Biosensors : Stents (2014)</li> <li>- Boston Scientific : Stents (2014)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2015)</li> <li>- Boston Scientific : Complex PCI (2015)</li> <li>- Sanofi Aventis : Managing Dyslipidemia (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medicines Company : Antithrombotic therapy (2014)</li> <li>- Johnson &amp; Johnson : Catheters (2014)</li> <li>- Edwards Lifesciences : Heartvalves (2014)</li> <li>- St Jude Medical : OCT (2014)</li> <li>- Abbott : Stent (2014)</li> <li>- Biotronik : Stent (2014)</li> <li>- Boston Scientific : Stent and Heartvalves (2014)</li> <li>- Medtronic : Stent and Heartvalves (2014)</li> <li>- Sorin Group : Electrophysiology (2015)</li> <li>- Biotronik : Electrophysiology (2015)</li> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Medicines Company : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Medtronic : Structural Heart Disease (2015)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Novartis : IMP (2015-2016)</li> <li>- Actelion : IMP (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015-2016)</li> <li>- Abbott : PCI and Structural Heart Disease (2015-2016)</li> <li>- Boston Scientific : Structural Heart Disease (2015-2016)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015-2016)</li> <li>- Symetis SA : Structural Heart Disease (2015-2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> <li>- Biotronik : Elektrophysiology (2016)</li> <li>- Amgen : General Cardiology (2016)</li> <li>- Takeda Pharmaceuticals : General Cardiology (2016)</li> <li>- Bristol Myers Squibb : General Cardiology (2016)</li> <li>- Bayer AG : General Cardiology (2016)</li> <li>- Biotest : General Cardiology (2016)</li> <li>- Comed : General Cardiology (2016)</li> <li>- Baxalta : General Cardiology (2016)</li> <li>- Medicure : General Cardiology (2016)</li> <li>- Sanofi Aventis : Heart Failure, General Cardiology (2016)</li> <li>- Qvanteq : Invasive Cardiology, PCI (2016)</li> <li>- St. Jude Medical : PCI (2016)</li> <li>- Medtronic : Structural Heart Disease (2016)</li> <li>- NVT AG : Structural Heart Disease (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Quintiles : Structural Heart Disease &amp; PCI (2016)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> <li>- Philips : 3D Echocardiography. (2016)</li> <li>- Servier : Clinical case presentation during ESC Cong 2016 (2016)</li> <li>- Pfizer : speaker CV risk factors. (2016)</li> <li>- MSD : speaker. CV risk factors (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> <li>- Edwards Lifesciences : Echo for TAVi assessment &amp; Epidemiology of Ao stenosis (2016)</li> <li>- Abbott : Epidemiology study of Mitral regurgitation (2016)</li> </ul>